Biogen | BIIB - Operating Expenses


Biogen reported $1.88B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Bayer EUR 10.2B 523M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Moderna USD 1.28B 232M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025